Revenue
2017
2018
2019
2020
Cogent Biosciences, Inc. (COGT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $7.9M | $22.5M | $9.7M | $8.4M |
| Research & development | $269.8M | $232.7M | $173.8M | $121.6M | $55.9M | $25.7M | $43.7M | $38.3M | $29.8M |
| Operating income | −$333.4M | −$275.9M | −$208.1M | −$147.8M | −$75.6M | −$82.2M | −$32.2M | −$36.0M | −$26.2M |
| EBITDAderived | −$330.8M | −$273.4M | −$205.8M | −$147.0M | −$75.4M | −$81.5M | −$30.9M | −$34.7M | −$25.0M |
| Net income | −$328.9M | −$255.9M | −$192.4M | −$140.2M | −$72.3M | −$74.8M | −$31.8M | −$34.5M | −$25.5M |
| Basic EPSper diluted share | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | -$16.17 | -$4.18 | -$1.39 | -$2.51 |
| Diluted EPSper diluted share | -$2.16 | -$1.94 | -$1.94 | -$1.73 | -$1.87 | -$16.17 | -$4.18 | -$1.39 | -$2.51 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 31, 2026Form 4 | Fairmount Funds Management LLCDirector | SellCommon Stock · indirect | 7.00M | $34.66 | $242.62M | 5.50M |
| Jan 22, 2026Form 4 | Fairmount Funds Management LLCDirector | SellCommon Stock · indirect | 3.50M | $36.40 | $127.40M | 5.50M |
| Dec 26, 2025Form 4 | Kearns EvanChief Legal Officer | SellCommon Stock | 65.0K | $38.70 | $2.52M | 109.4K |
| Dec 26, 2025Form 4 | Green John L.Chief Financial Officer | SellCommon Stock | 77.0K | $38.68 | $2.98M | 131.8K |
| Dec 26, 2025Form 4 | Sachs JessicaChief Medical Officer | SellCommon Stock | 82.6K | $38.70 | $3.20M | 133.9K |